Abbott Laboratories (MEX:ABT) EBIT: MXN158,856 Mil (TTM As of Mar. 2026)


MEX:ABT Abbott Laboratories MEX:ABT
81 GF Score
Price MXN1,605.00
GF Value MXN2,296.73
Valuation Significantly Undervalued
View Full Analysis

What is Abbott Laboratories EBIT?

Abbott Laboratories MEX:ABT +1.26% 81 EBIT is MXN158,856 Mil as of Mar. 2026. GuruFocus rates MEX:ABT with a GF Score™ of 81/100 and a GF Value™ of MXN2,296.73 (Significantly Undervalued).

Abbott Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was MXN29,267 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN158,856 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Abbott Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 was 5.21%. Abbott Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 49.26%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Abbott Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.89%.


Abbott Laboratories  (MEX:ABT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Abbott Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=97015.928 * ( 1 - 25.67% )/( (1157964.574 + 1610861.092)/ 2 )
=72111.9392824/1384412.833
=5.21 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1561328.265 - 242410.739 - ( 160952.952 - max(0, 297022.027 - 468076.177+160952.952))
=1157964.574

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1991333.03 - 251880.754 - ( 131548.547 - max(0, 331386.928 - 459978.112+131548.547))
=1610861.092

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Abbott Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=117068.288/( ( (212755.351 + max(17177.438, 0)) + (223190.728 + max(22198.253, 0)) )/ 2 )
=117068.288/( ( 229932.789 + 245388.981 )/ 2 )
=117068.288/237660.885
=49.26 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(142767.195 + 116820.982 + 5.8207660913467E-11) - (242410.739 + 0 + 0)
=17177.438

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(148048.467 + 126030.54 + 5.8207660913467E-11) - (251880.754 + 0 + 5.8207660913467E-11)
=22198.253

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Abbott Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=158856.314/3248653.530
=4.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abbott Laboratories EBIT Related Terms


Abbott Laboratories EBIT Historical Data

* Premium members only.

The historical data trend for Abbott Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbott Laboratories EBIT Chart

Abbott Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 179,374.42 172,812.54 123,928.99 157,919.36 161,313.07

Abbott Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39,054.70 42,761.11 42,210.00 44,618.13 29,267.07

MEX:ABT vs SYK, MDT, BSX: EBIT Comparison

For the Medical Devices subindustry, Abbott Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbott Laboratories EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Abbott Laboratories's EV-to-EBIT falls into.


MEX:ABT
81GF Score
Abbott Laboratories MEX:ABT
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abbott Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN158,856 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of MXN158,856 Mil mean?
Abbott Laboratories (MEX:ABT) has a EBIT of MXN158,856 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Abbott Laboratories.
Is Abbott Laboratories' EBIT too high?
Abbott Laboratories' current EBIT is MXN158,856 Mil. Overall, Abbott Laboratories has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' EBIT compare to SYK and MDT?
Abbott Laboratories' EBIT of MXN158,856 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Abbott Laboratories. Abbott Laboratories's current EBIT is MXN158,856 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (MEX:ABT) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,296.73, compared to a current price of MXN1,605.00 — trading 30.1% below its estimated fair value. The current EBIT is MXN158,856 Mil. Abbott Laboratories' overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Abbott Laboratories (MEX:ABT), the current EBIT is MXN158,856 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbott Laboratories (MEX:ABT) Overvalued in 2026?

Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued. The current stock price of MXN1,605.00 is trading 30.1% below its estimated GF Value™ of MXN2,296.73. GuruFocus considers Abbott Laboratories to be Significantly Undervalued.

Key valuation signals for MEX:ABT:

  • EBIT: MXN158,856 Mil
  • GF Value™: MXN2,296.73 vs. price of MXN1,605.00 (30.1% below fair value)
  • GF Score™: 81/100

No single metric tells the full story. See the MEX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Abbott Laboratories Business Description

Address 100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
81GF Score

Get the complete analysis for MEX:ABT

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,605.00
Price
MXN2,296.73
GF Value